Nanjing Legend Biotech Co., Ltd.

Legend Biotech Ireland Limited

Nanjingjinsirui Science & Technology Biology Corporation

Nanjing Legend Biotech., Ltd.

Shu Wu

Shuai Yang

Chuan-Chu Chou

Yafeng Zhang

Wang Zhang

Jianbing Zhang

Fang Liang Zhang

Qing Zhang

Tailan Zhan

Yuanyuan Peng

Jian Liu

Liusong Yin

Yun Zhang

Feng Lin

Zhongdao Li

Fangliang Zhang

Zhenyu Liu

Kun Jiang

Chenyu Shu

An Tang

Yunlei Liu

Xiaojie Tu

Qi Pan

Qing Dai

Fei Sun

Ruidong Hao

Sujuan Wang

Tao Zhao

Provided herein are anti-DLL3 chimeric antigen receptors (CARs), DLL3 binding proteins and uses of such CARs or DLL3 binding proteins in the treatment of DLL3 associated disorders, such as small cell lung cancer.

Anti-DLL3 chimeric antigen receptors and uses thereof

The present application provides single-domain antibodies targeting CD33 and constructs thereof, including chimeric receptors, immune effector cell engagers and immunoconjugates. Further provided are engineered immune cells (such as T cells) comprising an anti-CD33 chimeric receptor and optionally a second chimeric receptor targeting a second antigen or epitope. Pharmaceutical compositions, kits and methods of treating cancer are also provided.

Single-domain antibodies against CD33 and constructs thereof

The present application provides an antibody, such as a monoclonal antibody (mAb), or an antigen binding fragment thereof, that specifically recognizes PD-L1. Also provided are pharmaceutical compositions, or methods of making and using the antibody or antigen binding fragment thereof.

Antibodies and variants thereof against PD-L1

Provided are single-domain antibodies targeting CLL1 and constructs thereof, including chimeric receptors, immune effector cell engagers and immunoconjugates. Further provided are engineered immune effector cells (such as T cells) comprising an anti-CLL1 chimeric receptor and optionally a second chimeric receptor targeting a second antigen or epitope. Pharmaceutical compositions, kits and methods of treating cancer are also provided.

Single-domain antibodies against CLL1 and constructs thereof

The present application provides anti-LAG-3 constructs comprising a single-domain antibody (sdAb) that specifically recognizes LAG-3. Also provided are methods of making and using these constructs.

Single-domain antibodies against LAG-3 and uses thereof

Described herein are T cells engineered to express a chimeric antigen receptor (CAR), such as an anti-mesothelin CAR alone or in combination with a follicle-stimulating hormone receptor (FSHR) binding domain and/or a dominant negative transforming growth factor-β receptor II (dnTGFβRII) for the treatment of diseases associated with mesothelin expression. Also described are T cells engineered to express a modified T cell receptor (TCR).

Anti-mesothelin chimeric antigen receptor (CAR) constructs and uses thereof

Provided are constructs comprising a single-domain antibody (sdAb) moiety that specifically recognizes TIGIT. Also provided are methods of making and using these constructs.

Single-domain antibodies and variants thereof against TIGIT

Provided are constructs comprising a single-domain antibody (sdAb) moiety that specifically recognizes PD-1. Also provided are methods of making and using these constructs.

Single-domain antibodies and variants thereof against PD-1

The present application provides constructs comprising a single-domain antibody (sdAb) moiety that specifically recognizes PD-L1. Also provided are methods of making and using these constructs.

Single-domain antibodies and variants thereof against PD-L1

Novel antibodies, such as single domain antibodies (sdAbs), or antigen-binding fragments thereof that specifically bind a transferrin are described. Compositions, methods and systems for increasing the half-life of a target protein in a serum using an antibody or fragment thereof against a transferrin are also described.

Compositions and methods using a single-domain antibody binding transferrin and protein A for increasing protein half-life in serum

The present application provides constructs comprising a single-domain antibody (sdAb) moiety that specifically recognizes cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Also provided are methods of making and using these constructs.

Single-domain antibodies and variants thereof against CTLA-4

Disclosed herein are multispecific, such as bispecific, antigen binding proteins comprising a first antigen binding domain comprising a heavy chain variable domain and a light chain variable domain, and a second antigen binding domain comprising a single-domain antibody. Pharmaceutical compositions comprising the multispecific antigen binding proteins, kits and methods of use thereof are further provided.

Multispecific antigen binding proteins and methods of use thereof

Novel antibodies, such as single domain antibodies (sdAbs), or fragments thereof that specifically bind a transferrin are described. Compositions, methods and systems for increasing the half-life of a target protein in a serum using an antibody or fragment thereof against a transferrin are described.

Compositions and methods for increasing protein half-life in a serum

An improved method for producing humanized antibody or an antigen binding fragment thereof is described. The method, designated framework-assembly, bypasses the reliance on structural biology and the construction of large libraries. It is easier to implement and more efficient than the rational design and empirical methods. Also described are humanized antibodies produced by the method and related framework-assembly library.

Growing community of inventors

Nanjing, China

Shu Wu